You are here » Home » Companies ยป Company Overview » Medicamen Biotech Ltd

Medicamen Biotech Ltd.

BSE: 531146 Sector: Health care
NSE: MEDICAMEQ ISIN Code: INE646B01010
BSE 00:00 | 06 Feb 704.65 -5.70
(-0.80%)
OPEN

719.55

HIGH

720.95

LOW

701.00

NSE 00:00 | 06 Feb 705.35 -7.60
(-1.07%)
OPEN

712.95

HIGH

728.75

LOW

700.00

OPEN 719.55
PREVIOUS CLOSE 710.35
VOLUME 253
52-Week high 1219.00
52-Week low 558.80
P/E 64.94
Mkt Cap.(Rs cr) 891
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 719.55
CLOSE 710.35
VOLUME 253
52-Week high 1219.00
52-Week low 558.80
P/E 64.94
Mkt Cap.(Rs cr) 891
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Medicamen Biotech Ltd. (MEDICAMEQ) - Director Report

Company director report

Dear Shareholders

Your Directors have pleasure in presenting their Twenty Ninth AnnualReport of the Company together with the Audited Financial Statement for the financial yearended March 312022.

1. FINANCIAL HIGHLIGHTS

(Rs In Lakhs)

Particulars Standalone Consolidated
2021-22 2020-21 2021-22 2020-21
Revenue from operations 11544.52 11014.65 11544.52 11271.61
Other Income 172.01 75.40 172.01 75.40
Total Income 11716.53 11090.06 11716.53 11347.01
Profit Before Finance Cost Depreciation and Tax 2527.55 2033.49 2526.62 1997.77
Finance Cost 140.06 106.40 140.06 106.40
Depreciation 577.14 251.97 577.14 251.97
Profit before exceptional items and tax 1810.35 1675.12 1809.42 1639.40
Exceptional Items 1 -1 - -1 -
Profit Before Tax 1810.35 1675.12 1809.42 1639.40
Provision for Tax 397.69 414.51 397.69 414.51
Deferred Tax -77.98 11.94 -77.98 11.94
Profit for the year 1490.64 1248.66 1489.71 1212.94

2. PERFORMANCE REVIEW

On a consolidated basis the revenue for 2022 was Rs 11716.53 Lakhshigher by 3.26% over the previous year?s revenue of Rs 11347.01 Lakhs. The profitafter tax (PAT) attributable to shareholders for 2022 and 2021 was Rs 1489.71 Lakhs and1212.94 Lakhs respectively. The PAT attributable to shareholders for 2022 was registeringa growth of 22.82% over the PAT of 2021. On standalone basis the revenue for 2022 was Rs11716.53 Lakhs higher by 5.65% over the previous year?s revenue of Rs 11090.06Lakhs. The profit after tax (PAT) attributable to shareholders for 2022 and 2021 was Rs1490.64 Lakhs and 1248.66 Lakhs respectively. The PAT attributable to shareholders for2022 was registering a growth of 19.38% over the PAT of 2021.

3. CHANGE IN THE NATURE OF THE BUSINESS IF ANY

There is no change in the nature of the business of the Company duringthe year under review.

4. MATERIAL CHANGES AFFECTING THE COMPANY

There have been no material changes and commitments affecting thefinancial position of the Company between the end of the financial year and date of thisreport. There have been no changes in the nature of business of the Company.

5. DIVIDEND

The Directors are pleased to recommend a dividend of Rs 1 per share(i.e. 10%) on the Equity Shares of the Company of Rs 10 each for the year ended March312022 (previous year Rs 1 per share i.e. 10%). If the dividend as recommended above isdeclared at the ensuing Annual General Meeting ('AGM?) the total outflow towardsdividend on Equity Shares for the year would be Rs 122.16 Lakhs (previous year Rs 122.16Lakhs).

6. DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the Securities and Exchange Board ofIndia (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI ListingRegulations?) the Board of Directors of the Company have adopted a DividendDistribution Policy which aims to maintain a balance between profit retention and a fairsustainable and consistent distribution of profits among its Members. The said Policy isavailable on the website of the Company under the 'Investors? section athttps://www.medicamen. com/dividend-distribution-policy.

7. TRANSFER TO RESERVES

The Board of Directors have decided to retain the entire amount ofprofits for 2021-22 in the profit and loss account.

8. SHARE CAPITAL

The paid-up Equity Share Capital as on March 312022 was Rs 1221.66Lakhs. During the year under review the Company has not issued any shares.

9. SUBSIDIARIES JOINT VENTURES AND ASSOCIATE COMPANIES

As on March 31 2022 the Company has one wholly owned subsidiary"OPAL Pharmaceuticals Pty Ltd".

10. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements of the Company and its subsidiaryis prepared in accordance with Indian Accounting Standards notified under the Companies(Indian Accounting Standards) Rules 2015 ('Ind AS?). The Audited ConsolidatedFinancial Statements together with the Auditor?s Report thereon forms part of thisAnnual Report.

The Annual Financial Statements of the subsidiary and related detailedinformation will be made available to Members seeking information till the date of theAGM. They are also available on the website of the Company at https://www.medicamen.com//.The Consolidated Financial Statements reflect the operations of OPAL Pharmaceuticals PtyLimited

A report on the financial position of OPAL Pharmaceuticals Pty Ltd asper the Companies Act 2013 ('the Act?) is provided in Form AOC-1 which is attachedto the financial statements.

11. CREDIT RATINGS

There were no changes in the credit ratings of the Company during theyear under review. As on March 31 2022 the Company had a short-term credit rating ofCRISIL A3 and a long-term rating of CRISIL BBB- / Stable by CRISIL Limited for bank loanfacilities aggregating to Rs 42 Crores.

12. PARTICULARS OF LOANS GUARANTEES OR INVESTMENTS

During the year under review the Company has not made any investment.Further the Company has not given any loan or corporate guarantee or provided anysecurity during the year.

Details of loans guarantees and investments covered under theprovisions of Section 186 of the Act are given in the notes to the Financial Statements.

13. RELATED PARTY TRANSACTIONS

The Company formulated a Policy on Related Party Transactions inaccordance with the Act and the SEBI

Listing Regulations including any amendments thereto for identifyingreviewing approving and monitoring of Related Party Transactions ('RPTs?). The saidPolicy has been revised in line with the amended SEBI Listing Regulations and the same isavailable on the Company?s website at https://www.medicamen.com/ RPTPolicy .

All RPTs are placed before the Audit Committee for review and approval.Prior omnibus approval of the Audit Committee is obtained on an annual basis for thetransactions which are planned/repetitive in nature. All the RPTs under Ind AS-24 havebeen disclosed in Standalone Financial Statements forming part of this Integrated AnnualReport.

The RPTs entered into during the year under review were on arm?slength basis in the ordinary course of business and were in compliance with theapplicable provisions of the Act read with the rules framed thereunder and the SEBIListing Regulations. Further the Company did not enter into any contracts or arrangementswith related parties in terms of Section 188(1) and no material related party transactionswere entered into during the year under review.

Accordingly the disclosure of RPTs as required under Section 134(3)(h)of the Act in Form No. AOC- 2 is not applicable to the Company for 2021-22. Theinformation on transactions with related parties pursuant to Section 134(3)(h) of the Actread with Rule 8(2) of the Companies (Accounts) Rules 2014 are given in "AnnexureB" in Form No. AOC-2 and the same forms part of this report.

In terms of Regulation 23 of the SEBI Listing Regulations the Companysubmits details of RPTs on a consolidated basis as per the format specified in therelevant accounting standards to the stock exchanges on a half-yearly basis.

14. RISK MANAGEMENT

The Company has a well defined risk management framework in place toidentify evaluate monitor business risks and challenges across the Company as well as toidentify new and emergent risks. The Company?s success as an organization largelydepends on its ability to identify opportunities and leverage them while mitigating therisks that arise while conducting its business.

The Risk Register is revisited periodically to ensure that the risksremain relevant at any point in time and corresponding mitigation measures are effective.This provides a proactive and value adding independent review process which enablesmaintaining the risk

profile at an acceptable level in a rapidly changing environment.Further for appropriate identification and mapping of risks the Company designs a RiskSlate focussing on two parameters - likelihood of the incident/event and its impact on thebusiness. Risks that fall under both these parameters are tagged as key risks for thepurpose of timely tracking and preparing mitigation plans. During the year under reviewthe Risk Management Policy and Terms of Reference of the Risk Management Committee wererevised in line with the SEBI Listing Regulations to inter alia set up strategicpolicies including focus on ESG related risks cyber security risks and defining the roleand responsibilities of the Risk Management Committee.

The Risk Management Committee is chaired by an Independent Director andthe Chairperson of the Audit Committee is also a member of the said Committee. Furtherthe Board is apprised of any procedure that may impact the long-term plans of the Company.

The major risks forming part of the Risk Management process are linkedto the audit universe and are also covered as part of the annual risk based audit plan.

15. INTERNAL FINANCIAL CONTROLS

The Company has a formal framework of Internal Financial Control inalignment with the requirement of Companies Act 2013 and has also laid down specificresponsibilities on the Board Audit Committee Independent Directors and StatutoryAuditors with regard to Internal Financial Control.

Accordingly the Company has a well-placed proper and adequateInternal Financial Control system which ensures:

• The orderly and efficient conduct of its business

• Safeguarding of its assets

• The prevention and detection of frauds and errors

• The accuracy and completeness of the accounting records and

• The timely preparation of reliable financial information.

The Board reviews the effectiveness of controls documented as part ofInternal Financial Control framework and take necessary corrective and preventive actionswherever weaknesses are identified as a result of such reviews. This review covers entitylevel controls process level controls fraud risk controls and Information Technologyenvironment.

Based on this evaluation no significant events had come to noticeduring the year that have materially affected or are reasonably likely to materiallyaffect our Internal Financial Control. The management has also come to a conclusion thatthe Internal Financial Control and other financial reporting was effective during the yearand is adequate considering the business operations of the Company.

16. DIRECTORS' RESPONSIBILITY STATEMENT

In terms of Sections 134(3)(c) and 134(5) of the Act the Directors tothe best of their knowledge and ability confirm that for the year ended March 312022:

(i) in the preparation of the annual accounts the applicableaccounting standards have been followed and that there are no material departures;

(ii) they have selected such accounting policies and applied themconsistently and made judgments and estimates that are reasonable and prudent so as togive a true and fair view of the state of affairs of the Company at the end of thefinancial year and of the profit of the Company for that period;

(iii) they have taken proper and sufficient care for the maintenance ofadequate accounting records in accordance with the provisions of the Act for safeguardingthe assets of the Company and for preventing and detecting fraud and other irregularities;

(iv) they have prepared the annual accounts on a going concern basis;

(v) they have laid down internal financial controls to be followed bythe Company and that such internal financial controls are adequate and are operatingeffectively; and

(vi) they have devised proper systems to ensure compliance with theprovisions of all applicable laws and that such systems are adequate and operatingeffectively.

17. GOVERNANCE COMPLIANCE AND ETHICS

The Governance Corporate Secretarial and Legal functions of theCompany ensure maintenance of good governance within the organization. They assist thebusiness in functioning smoothly by ensuring compliance and providing strategic businesspartnership in the areas including legislative expertise corporate restructuringregulatory changes and governance.

The Company has also adopted the governance guidelines on Boardeffectiveness to fulfil its responsibility towards its stakeholders. With a view to upholdhuman rights as an integral aspect of doing business being committed to respect andprotect human rights and remediate adverse human rights impact resulting from or caused bythe Company?s businesses the Board adopted 'Business and Human Rights Policy?during the year under review.

In compliance with the SEBI Listing Regulations the CorporateGovernance Report and the Auditor?s Certificate form part of this Integrated AnnualReport.

18. MANAGEMENT DISCUSSION & ANALYSIS

Various business aspects including market conditions businessopportunities challenges etc. have been discussed at length in the Management?sDiscussion and Analysis (MD&A) which forms part of this Annual Report.

19. BUSINESS RESPONSIBILITY REPORT (BRR)

The Listing Regulations mandate the inclusion of the BRR as part of theAnnual Report for top 1000 listed entities based on market capitalization. In accordancewith the Listing Regulations we have integrated BRR disclosures into our Annual Report.

20. DIRECTORS AND KEY MANAGERIAL PERSONNEL Re-appointment:

In accordance with the provisions of Section 152 of the Act and interms of Article 112(2) of the Articles of Association of the Company Dr. Vimal KumarShrawat and Mr. Sanjay Bansal Non-Executive Directors of the Company retires by rotationat the ensuing AGM and being eligible offers himself for re-appointment IndependentDirectors:

Mr. Harish Pande Mr. Arun Kumar Mrs. Sumita Dwivedi Mrs. SangeetaBishnoi and Dr Ravi Kumar Bansal Independent Directors of the Company have givendeclarations that they meet the criteria of independence as laid down under Section 149(6)of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations. In terms of Regulation25(8) of the SEBI Listing Regulations the Board of Directors of the Company has taken onrecord the declaration and confirmation submitted by the Independent Directors afterundertaking due assessment of the veracity of the same.

The Board is of the opinion that all Directors including theIndependent Directors of the Company possess requisite qualifications integrityexpertise and experience in the fields of science and technology industry experiencestrategy finance and governance

IT and digitalization human resources safety and sustainability etc.

During the year under review the Non-Executive Directors of theCompany had no pecuniary relationship or transactions with the Company.

Key Managerial Personnel f'KMP'l:

In terms of the provisions of Sections 2(51) and 203 of the Act thefollowing are the KMP of the Company:

• Mr. Rajesh Madan CEO

• Mr. Pratap Singh Rawat Chief Financial Officer

• Ms. Parul Choudhary Company Secretary Procedure for Nominationand Appointment of Directors:

The NRC is responsible for developing competency requirements for theBoard based on the industry and strategy of the Company. The Board composition analysisreflects in-depth understanding of the Company including its strategies environmentoperations financial condition and compliance requirements.

The NRC is also responsible for reviewing the profile of potentialcandidates vis-a-vis the required competencies and meeting potential candidates prior tomaking recommendations of their nomination to the Board.

Criteria for determining Qualifications Positive Attributes andIndependence of a Director:

The NRC has formulated the criteria for determining qualificationspositive attributes and independence of Directors in terms of provisions of Section 178(3)of the Act and Regulation 19 read with Part D of Schedule II to the SEBI ListingRegulations.

Independence: In accordance with the above criteria a Director will beconsidered as an 'Independent Director? if he / she meets the criteria forIndependence as laid down in the Act and Rules framed thereunder as amended andRegulation 16(1)(b) of the SEBI Listing Regulations.

Qualifications: A transparent Board nomination process is in place thatencourages diversity of thought experience knowledge perspective age and gender. It isalso ensured that the Board has an appropriate blend of functional and industry expertise.While recommending the appointment of a Director the NRC considers the manner in whichthe function and domain expertise of the individual will contribute to the overallskill-domain mix of the Board.

Positive Attributes: In addition to the duties as prescribed under theAct the Directors on the Board of the Company are also expected to demonstrate highstandards of ethical behaviour strong interpersonal and communication skills andsoundness of judgement. Independent Directors are also expected to abide by the 'Code forIndependent Directors? as outlined in Schedule IV to the Act.

Annual evaluation of board performance and performance of itscommittees and directors:

Pursuant to the applicable provisions of the Act and the SEBI ListingRegulations the Board has carried out an annual evaluation of its own performanceperformance of the Directors as well as the evaluation of the working of its Committees.

The NRC has defined the evaluation criteria procedure and timeschedule for the Performance Evaluation process for the Board its Committees andDirectors. Remuneration Policy

The Company has adopted a Remuneration Policy for the Directors KMPand other employees pursuant to the provisions of the Act and the SEBI ListingRegulations and the same is available on the Company?s website athttps://www.medicamen.com/ NominationandremunerationPolicy .

21. BOARD AND COMMITTEE MEETINGS

Regular meetings of the Board and its Committees are conducted todiscuss and approve various strategies policies financial matters and such otherbusinesses. A calendar of Board and Committee Meetings to be held during the year wascirculated in advance to the Directors.

a. Details of Board Meetings

During the year under review four (4) Board Meetings were helddetails of which are provided in the Corporate Governance Report.

b. Composition of Audit Committee

As on March 31 2022 the Audit Committee comprised three (3) Membersthey all are Independent Directors. During the year four (4) Audit Committee Meetingswere held details of which are provided in the Corporate Governance Report.

There have been no instances during the year when recommendations ofthe Audit Committee were not accepted by the Board.

c. Composition of Corporate Social Responsibility ('CSR') Committee

During the year under review the CSR Committee comprised four (4)Members out of which one (!) was an Independent Director and two (2) were Non-IndependentNon-Executive Directors and (!) is Chief Executive Officer of the Company. During the yearunder review four (4) CSR Committee Meetings were held details of which are provided inthe Corporate Governance Report. There have been no instances during the year whenrecommendations of the CSR Committee were not accepted by the Board.

Details on other committees including their composition number ofmeetings held and terms of reference are included in the Corporate Governance Report.

22. POLICY ON PREVENTION PROHIBITION AND REDRESSAL OF SEXUALHARASSMENT AT WORKPLACE

The Company has zero tolerance for sexual harassment at workplace andhas adopted a Policy on Prevention Prohibition and Redressal of Sexual Harassment in linewith the requirements of the Sexual Harassment of Women at Workplace (PreventionProhibition and Redressal) Act 2013 ('POSH Act?) and the rules framed thereunder.Internal Committees have been set up to redress complaints received regarding sexualharassment. All persons whether employed as permanent contractual temporary or traineesare covered under this Policy. No complaints were pending at the beginning of 2021-22.Further the Company did not receive any complaints of sexual harassment during the yearunder review and accordingly there were no complaints pending as at the end of thefinancial year. The said Policy is available on the website of the Company athttps://www.medicamen. com/posh-policy .

As an endeavour to educate and empower the women employees within theorganization regarding POSH and their rights virtual awareness sessions were alsoconducted during 2021-22.

23. VIGIL MECHANISM AND WHISTLEBLOWER POLICY

The Company established a whistleblower policy in order to assure thatthe business is conducted with integrity and that the Company?s financial informationis accurate.

Details of the Vigil Mechanism and Whistle-blower Policy are madeavailable on the Company?s website at https://www.medicamen.com/WhistleblowerPolicy.

24. AUDITORS

(1) Statutory Auditors

At the 24th AGM of the Company held on September 13 2017pursuant to the provisions of the Act and the Rules made thereunder M/s Rai Qimat &Associates Chartered Accountants Delhi (Firm Registration No. 013152C) were appointedas Statutory Auditors of the Company from the conclusion of the 24th AGM tillthe conclusion of the 29th AGM to be held in the year 2022.

The Audit Report of M/s Rai Qimat & Associates on the FinancialStatements of the Company for 2021-22 forms part of this Integrated Annual Report. TheReport does not contain any qualification reservation adverse remark or disclaimer.

The Board of Directors of the Company at its Meeting held on May 252022 based on the recommendation of the Audit Committee reappointed M/s Rai Qimat &Associates as the Statutory Auditors of the Company pursuant to Section 139 of the Act fora second term of five (5) consecutive years i.e. from the conclusion of the 29thAGM till the conclusion of the 34th AGM to be held in the year 2027 subject toapproval by the Members at the ensuing 29th AGM of the Company.

Accordingly an Ordinary Resolution proposing the re-appointment of M/sRai Qimat & Associates as the Statutory Auditors of the Company for a second term offive (5) consecutive years is set out in the Notice of the 29th AGM formingpart of this Integrated Annual Report. The Company has received their written consentalong with the eligibility certificate confirming that they satisfy the criteria providedunder Section 141 of the Act and that the re-appointment if made shall be in accordancewith the applicable provisions of the Act and rules framed thereunder.

(2) Secretarial Audit

Pursuant to provisions of section 204 of the Companies Act 2013 andthe Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 the Boardhas appointed M/s AMJ & Associates a firm of Company Secretaries in practice toundertake the Secretarial Audit of the Company. The Secretarial Audit report for thefinancial year ended March 31 2022 is annexed herewith as "Annexure A". TheSecretarial Auditor report does not contain any qualification reservation adverse remarkor disclaimer.

(3) Cost Auditor

The Company is required under Section 148(1) of the Companies Act 2013read with Companies (Audit & Auditors?) Rules 2014 and the Companies (CostRecords and Audit) Amendments Rules 2014 the Company is required to maintain the costrecords in respect of its business and accordingly such accounts and records are made andmaintained.

I n terms of Section 148 of the Act read with the Companies (CostRecords and Audit) Rules 2014 the Audit Committee recommended and the Board of Directorsappointed M/s SPB & Co. Cost Auditors (Firm Registration No. 102586) being eligibleto conduct Cost Audits relating to Drugs and Pharmaceuticals of the Company for the yearending March 31 2023. The Company has received their written consent and confirmationthat the appointment will be in accordance with the applicable provisions of the Act andrules framed thereunder.

The remuneration payable to Cost Auditors has been approved by theBoard of Directors on the recommendation of the Audit Committee and in terms of the Actand Rules therein. The Members are therefore requested to ratify the remuneration payableto M/s SPB & Co. Cost Auditors as set out in the Notice of the 29th AGM ofthe Company.

M/s SPB & Co. Cost Auditors have confirmed that they are freefrom disqualification specified under Section 141(3) and proviso to Section 148(3) readwith Section 141(4) of the Act and that their appointment meets the requirements ofSection 141(3)(g) of the Act. They have further confirmed their independent status and anarm?s length relationship with the Company. The remuneration payable to the CostAuditors is required to be placed before the Members in a General Meeting for theirratification. Accordingly a resolution for seeking Members? ratification for theremuneration payable to M/s SPB & Co is included in the Notice of the 29thAGM forming part of this Integrated Annual Report.

(4) Internal Auditor

Pursuant to provision of Section 138 of the Companies Act 2013 readwith Companies (Accounts) Rules 2014.The Board of Directors based on the recommendationof the Audit Committee has re-appointed M/s Cheena & Associates Cost Accountants(Firm Registration Number: 00397) as the Internal Auditors of your Company.

25. REPORTING OF FRAUDS BY AUDITORS

There are no Auditors? Qualifications or reservations or adverseremarks on the financial statements of the Company. The Auditors have not reported anyfrauds to the Audit Committee as prescribed under Section 143(12) of the Companies Act2013.

26. ANNUAL RETURN

Pursuant to Section 92(3) of the Act and Rule 12 of the Companies(Management and Administration) Rules 2014 read with Section 134(3)(a) of the Act theAnnual Return in Form MGT-7 as on March 31 2022 is available on the Company?swebsite at https://www. medicamen.com/MGT2022.htm.

27. SECRETARIAL STANDARDS

The Company has devised proper systems to ensure compliance with theprovisions of all applicable Secretarial Standards issued by the Institute of CompanySecretaries of India and that such systems are adequate and operating effectively.

28. PERFORMANCE EVALUATION

The formal annual evaluation of the performance of the Board as well asnon-independent directors was undertaken by the Nomination and Remuneration Committee. Theperformance of Board Committees and of individual independent directors was undertaken bythe Board members.

The manner of the evaluation of the Board and other Committees has beendetermined by the Nomination and Remuneration Committee as per SEBI circular dated January5 2017.

29. UNCLAIMED DIVIDEND

(a) Transfer to Investor Education and Protection Fund

Pursuant to Sections 124 and 125 of the Act read with the InvestorEducation and Protection Fund Authority (Accounting Audit Transfer and Refund) Rules2016 ("IEPF Rules") dividend if not claimed for a period of 7 years from thedate of transfer to Unpaid Dividend Account of the Company are liable to be transferredto the Investor Education and Protection Fund ("IEPF").

Further all the shares in respect of which dividend has remainedunclaimed for seven consecutive years or more from the date of transfer to unpaid dividendaccount shall also be transferred to IEPF Authority. The said requirement does not applyto shares in respect of which there is a specific order of Court Tribunal or StatutoryAuthority restraining any transfer of the shares.

The details of unclaimed dividends and shares transferred to IEPF areas follows:

Financial Year Amount of unclaimed dividend Transferred (Rs) Number of shares transferred
2009-10 287303.25 134393

Members/ claimants whose shares unclaimed dividend sale proceeds offractional shares etc. have been transferred to the IEPF Demat Account or the Fund as thecase may be may claim the shares or apply for refund by making an application to the IEPFAuthority in Form IEPF- 5 (available on iepf.gov.in) along with requisite fee as decidedby the IEPF Authority from time to time. The Member/ Claimant can file only oneconsolidated claim in a financial year as per the IEPF Rules.

The following tables give information relating to various outstandingdividends and the dates by which they can be claimed by the shareholders from theCompany?s Registrar and Transfer

Anont-

Financial Year Date of Declaration Last date for claiming unpaid Dividend
2017-18 02.08.2017 01.09.2024
2018-19 25.09.2019 25.10.2026
2019-20 25.09.2020 25.10.2027
2020-21 25.09.2021 25.10.2028

30. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant material orders passed by the Regulators orCourts which would impact the going concern status of the Company and its futureoperations.

31. CONSERVATION OF ENERGY TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGEEARNINGS AND OUTGO

The information on conservation of energy technology absorption andforeign exchange earnings and outgo

stipulated under Section 134(3)(m) of the Act read with Rule 8 of theCompanies (Accounts) Rules 2014 is attached as "Annexure E" which forms part ofthis Report.

32. PARTICULARS OF EMPLOYEES AND REMUNERATION

In terms of the provisions of Section 197(12) of the Companies Act2013 read with Rule 5 of the Companies (Appointment and Remuneration of ManagerialPersonnel) Rules 2014 disclosures pertaining to remuneration and other details areprovided in the "Annexure D" to this Report.

33. CORPORATE SOCIAL RESPONSIBILITY

A report on CSR Activities as required under Rule 9 of the Companies(Corporate Social Responsibility) Rules

2014 is enclosed herewith as "Annexure - C". The Company hasadopted Corporate Social Responsibility Policy containing the activities to be undertakenby the Company as part of its CSR programs. The CSR Policy is disclosed on the website ofthe Company www.medicamen.com

34. LISTING ON STOCK EXCHANGES

The Company?s shares are listed on BSE Limited since 1995 and lastyear on October 27 2021 we got listed on the National Stock Exchange of India Limited aswell.

35. HUMAN RESOURCE DEVELOPMENT

Attracting enabling and retaining talent have been the cornerstone ofthe Human Resource function and the results underscore the important role that humancapital plays in critical strategic activities such as growth.

The Company had total 357 employees as on March 312022.

36. EXPORT HOUSE STATUS

Your Company enjoys the status of "One Star Export House"

40. POLICIES AS PER SEBI (LISTING OBLIGATIONS AND DISCLOSUREREQUIREMENTS) REGULATIONS 2015

Pursuant to requirements of provisions of SEBI (Listing Obligations andDisclosure Requirements) Regulations

2015 the Company has adopted the following policies currently which areavailable on the portal of the Company (www. medicamen.com).

• Policy for Preservation of Documents

• Whistle Blower Policy

• Policy on Performance Evaluation

• Policy on Risk Management

• Policy on Remuneration of Directors and Key Managerial personal

• Policy on Archival of Documents

• Policy on Material Related Party Transactions

• Terms and condition of appointment of Independent Directors

• Policy on Sexual harassment of Women at Workplace

• Code of Insider Trading 41 GREEN INITIATIVE

Your Directors would like to draw your attention to section 20 of theCompanies act 2013 read with the Companies (Management and administration) Rules 2014 asmay be amended from time to time which permit the paperless compliances and also serviceof notice/documents (including annual report) through electronic mode to its shareholders.

Your Directors hereby once again appeal to all those members who havenot registered their e mail address so far are requested to register their email addressin respect of electronic holding with their concerned Depository participants and /or withthe Company.

42. HEALTH SAFETY AND ENVIRONMENT

Your Company recognizes the protection and management of environmentsas one of the highest priorities and every effort is made to conserve and protect theenvironment. During the year your Company continued its focus in creating as aestheticenvironment friendly Industrial habitant in its factory unit mobilizing supportgenerating interest among staff and labors for maintaining hygienic and greensurroundings. The Company obtained the necessary approval/Licenses from concernedGovernment Department/Pollution Control Board and related environment clearance safetyclearance. The Company continues to focus on maintenance and performance improvement ofrelated pollution control facility at its manufacturing locations.

43. CODE OF CONDUCT:

The Board of Directors has approved a Code of Conduct which isapplicable to the Members of the Board and all employees in the course of day-to-daybusiness operations of the Company. The Company believes in "Zero Tolerance"against bribery corruption and unethical dealings / behaviors of any form and the Boardhas laid down the directives to counter such acts. The Code has been posted on theCompany?s website www.medicamen.com. The Code lays down the standard procedure ofbusiness conduct which is expected to be followed by the Directors and the designatedemployees in their business dealings and in particular on matters relating to integrity inthe work place in business practices and in dealing with stakeholders.

44. OTHER DISCLOSURES

• No significant material orders have been passed by theRegulators or Courts or Tribunals which would impact the going concern status of theCompany and its future operations

• No applications were made or any proceedings were pendingagainst the Company under the Insolvency and Bankruptcy Code 2016

• No deposits have been accepted from the public during the yearunder review and no amount on account of principal or interest on deposits from the publicwas outstanding as on March 312022

• There has been no change in the nature of business of theCompany as on the date of this Report

• There were no material changes and commitments affecting thefinancial position of the Company between the end of the financial year and the date ofthis Report

45. ACKNOWLEDGEMENT

The Directors appreciate and value the contribution dedication hardwork and commitment made by all the employees and acknowledge the support extended bythem during these challenging times.

The Directors would also like to place on record their appreciation forthe continued co-operation and support received by the Company during the year frombankers financial institutions government authorities farming community businesspartners shareholders customers and other stakeholders. The Directors look forward tocontinuance of the supportive relations and assistance in the future.

The Directors deeply regret the losses suffered due to the Covid-19pandemic and place on record their sincere appreciation to all the front-line workers andall who have gone beyond their duties in battling against the pandemic.

By the Order of the Board
Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Place: New Delhi Chairman
Date: 10.08.2022 DIN-00317960

.